Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): A randomised multicentre, open-label, phase 3 study

The Lancet Oncology

Volumn 13, Issue 3, 2012, Pages 300-308

  Ciuleanu, Tudor ^a   Stelmakh, Lilia ^b   Cicenas, Saulius ^c   Miliauskas, Skaidrius ^d   Grigorescu, Alexandru Calin ^e   Hillenbach, Carina ^f   Johannsdottir, Hrefna Kristin ^f   Klughammer, Barbara ^f   Gonzalez, Emilio Esteban ^g  

^a THE ONCOLOGY INSTITUTE PROF DR ION CHIRICUTA   (Romania)

^b PAVLOV FIRST SAINT PETERSBURG STATE MEDICAL UNIVERSITY   (Russian Federation)

^c VILNIUS UNIVERSITY   (Lithuania)

^d LITHUANIAN UNIVERSITY OF HEALTH SCIENCES   (Lithuania)

^e Institutul Oncologic Prof Dr Alexandru Trestioreanu Bucuresti   (Romania)

^f F HOFFMANN LA ROCHE LTD   (Switzerland)

^g HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; ERLOTINIB; GEMCITABINE; NAVELBINE; PACLITAXEL; PEMETREXED; PLATINUM COMPLEX;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DEATH; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY EYE; DRY SKIN; EGFR GENE; FATIGUE; FEMALE; FOLLOW UP; GENE; GENE MUTATION; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MYALGIA; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PARONYCHIA; PERFORMANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SMOKING; STOMATITIS; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CHI-SQUARE DISTRIBUTION; EARLY TERMINATION OF CLINICAL TRIALS; EUROPE; FEMALE; GLUTAMATES; GUANINE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SALVAGE THERAPY; TAXOIDS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84857501696     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(11)70385-0     Document Type: Article

References (18)

1. Favaretto AG, Pasello G, Magro C Second and third line treatment in advanced non-small cell lung cancer. Discov Med 2009, 8:204-209.
2. Di Maio M, Chiodini P, Georgoulias V, et al. Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 2009, 27:1836-1843.
3. Smit EF, Burgers SA, Biesma B, et al. Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer. J Clin Oncol 2009, 27:2038-2045.
4. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000, 18:2095-2103.
5. Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000, 18:2354-2362.
6. Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008, 372:1809-1818.
7. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004, 22:1589-1597.
8. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353:123-132.
9. Cappuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010, 11:521-529.
10. Brugger W, Triller N, Blasinska-Morawiec M, et al. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer. J Clin Oncol 2011, 29:4113-4120.
11. Douillard JY, Shepherd FA, Hirsh V, et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol 2010, 28:744-752.
12. Pocock SJ, Simon R Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975, 31:103-115.
13. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005, 97:339-346.
14. Shepherd FA, Tsao MS Unraveling the mystery of prognostic and predictive factors in epidermal growth factor receptor therapy. J Clin Oncol 2006, 24:1219-1220.
15. Yauch RL, Januario T, Eberhard DA, et al. Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin Cancer Res 2005, 11:8686-8698.
16. Sos ML, Michel K, Zander T, et al. Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. J Clin Invest 2009, 119:1727-1740.
17. Zhu CQ, da Cunha Santos G, Ding K, et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008, 26:4268-4275.
18. Vamvakas L, Agelaki S, Kentepozidis NK, et al. Pemetrexed (MTA) compared with erlotinib (ERL) in pretreated patients with advanced non-small cell lung cancer (NSCLC): results of a randomized phase III Hellenic Oncology Research Group trial. Proc Am Soc Clin Oncol 2010, 28(suppl). abstr 7519.